This study was to report proxy measures for mortality risk in patients with hematological malignancies across 185 countries globally and explore its association with their socioeconomic status and treatment. The incidence, mortality, and 5-year prevalence data were extracted from the GLOBOCAN database. The data regarding the human development index (HDI), gross national income (GNI), vulnerability index, and concordance with cancer Essential Medicines List (EML) were obtained from open-source reports. The ratio of mortality to 5-year-prevalence (MPR) and that of mortality to incidence (MIR) were calculated and age-standardized using Segi's world standard population. Finally, the possible associations were assessed using Pearson correlation analyses. In 2020, the global incidence, mortality, and 5-year prevalence of HMs were 1,278,362, 711,840, and 3,616,685, respectively. Global age-standardized MPR and MIR were 0.15 and 0.44, respectively; they varied significantly among 6 regions, 185 countries, 4 HM types, and 4 HDI groups worldwide. Older populations always had higher ratios. The correlation of MPRs and MIRs with HDI, GNI, and concordance with cancer EML was negative, whereas it was positive with the vulnerability index (lower was better). Increasing access to cancer drugs in resource-limited regions with a focus on vulnerable children may aid in reducing HM-related mortality risk.

中文翻译：

---

185 个国家血液系统恶性肿瘤诊断后死亡风险的差异：全球数据分析

本研究旨在报告全球 185 个国家血液恶性肿瘤患者死亡风险的替代指标，并探讨其与社会经济状况和治疗的关系。发病率、死亡率和 5 年患病率数据从 GLOBOCAN 数据库中提取。有关人类发展指数（HDI）、国民总收入（GNI）、脆弱性指数以及与癌症基本药物清单（EML）一致性的数据均来自开源报告。使用 Segi 的世界标准人口计算死亡率与 5 年患病率 (MPR) 的比率以及死亡率与发病率 (MIR) 的比率并进行年龄标准化。最后，使用皮尔逊相关分析评估了可能的关联。 2020年，全球HMs发病率、死亡率和5年患病率分别为1,278,362、711,840和3,616,685。全球年龄标准化 MPR 和 MIR 分别为 0.15 和 0.44；它们在全球 6 个地区、185 个国家、4 个 HM 类型和 4 个 HDI 组之间存在显着差异。老年人口的比例总是较高。 MPR 和 MIR 与 HDI、GNI 以及与癌症 EML 的一致性呈负相关，而与脆弱性指数呈正相关（越低越好）。在资源有限的地区增加抗癌药物的获取，重点关注弱势儿童，可能有助于降低与 HM 相关的死亡风险。